TICKERNOMICS Sign up
Last Update: 2024-12-27 15:28:44
BioAtla Inc. ( BCAB ) https://www.bioatla.com
0.64USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-77.22%
BCAB
SPY
32.66%
-96.71%
BCAB
SPY
108.59%
BCAB
0.00%
SPY
302.52%
BCAB
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
29.53
-25.06
1.40
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.36
2.24
1.29
-100.04
0.00
0.37
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-102.45
100.00
-154.65
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-46.25
-46.93
0.00
Other Earnings and Cash Flow Stats:
BioAtla Inc. ( BCAB ) Net Income TTM ($MM) is -81.82
BioAtla Inc. ( BCAB ) Operating Income TTM ($MM) is -86.24
BioAtla Inc. ( BCAB ) Owners' Earnings Annual ($MM) is 0.00
BioAtla Inc. ( BCAB ) Current Price to Owners' Earnings ratio is 0.00
BioAtla Inc. ( BCAB ) EBITDA TTM ($MM) is -85.17
BioAtla Inc. ( BCAB ) EBITDA Margin is -154.65%
Capital Allocation:
BioAtla Inc. ( BCAB ) has paid 0.00 dividends per share and bought back -0.501725 million shares in the past 12 months
BioAtla Inc. ( BCAB ) has reduced its debt by 0.923 million USD in the last 12 months
Capital Structure:
BioAtla Inc. ( BCAB ) Interest-bearing Debt ($MM) as of last quarter is 1
BioAtla Inc. ( BCAB ) Annual Working Capital Investments ($MM) are -7
BioAtla Inc. ( BCAB ) Book Value ($MM) as of last quarter is 22
BioAtla Inc. ( BCAB ) Debt/Capital as of last quarter is 3%
Other Balance Sheet Stats:
BioAtla Inc. ( BCAB ) has 56 million in cash on hand as of last quarter
BioAtla Inc. ( BCAB ) has 19 million of liabilities due within 12 months, and long term debt 0 as of last quarter
BioAtla Inc. ( BCAB ) has 48 common shares outstanding as of last quarter
BioAtla Inc. ( BCAB ) has 0 million USD of preferred stock value
Academic Scores:
BioAtla Inc. ( BCAB ) Altman Z-Score is -12.30 as of last quarter
BioAtla Inc. ( BCAB ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
BioAtla Inc. ( BCAB ) largest shareholder is owning shares at 0.00 ($MM) value
Sylvia Mcbrinn(an insider) Bought 4000 shares of BioAtla Inc. ( BCAB ) for the amount of $9320.00 on 2023-12-26
10.76% of BioAtla Inc. ( BCAB ) is held by insiders, and 50.87% is held by institutions
BioAtla Inc. ( BCAB ) went public on 2020-12-16
Other BioAtla Inc. ( BCAB ) financial metrics:
FCF:-85.09
Unlevered Free Cash Flow:0.00
EPS:-0.88
Operating Margin:-102.45
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-184.36
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About BioAtla Inc. ( BCAB ) :
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.